Displaying drugs 11376 - 11400 of 11784 in total
Edratide
Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Investigational
Matched Description: … Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, …
Ravoxertinib
Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 …
Ridinilazole
Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).
Investigational
Matched Description: … Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With …
NDX-3315
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … It is a technetium-99m radiolabeled [heparin]. …
ZYCOV-D
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid ... Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a …
Zalutumumab
Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
Investigational
Matched Description: … Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal …
PZM21
PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine.
Experimental
Matched Description: … PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment …
EGT-101
EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.
Investigational
Matched Description: … Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A. …
XTL-001
XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B virus (HBV).
Investigational
MLN-977
MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Investigational
Matched Description: … MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase …
Fucoxanthin
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green ... A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing. …
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Morphine glucuronide
Investigational
Dirlotapide
Dirlotapide is a drug employed in the treatment of obesity in dogs. It is marketed by Pfizer and Zoetis under the brand name, Slentrol, and is not intended for human use.
Investigational
Vet approved
Matched Description: … Dirlotapide is a drug employed in the treatment of obesity in dogs. …
S-777469
S-777469 is under investigation in clinical trial NCT00703573 (A Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis).
Investigational
Matched Description: … S-777469 is under investigation in clinical trial NCT00703573 (A Randomized, Double-blind Study to Evaluate …
SBT101
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
Matched Description: … SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector …
Interleukin-7
Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Investigational
SC-236
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been …
Zatolmilast
BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).
Investigational
Matched Description: … BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 …
Fosifloxuridine nafalbenamide
Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
Investigational
Matched Description: … Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of …
Seltorexant
Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
Investigational
Matched Description: … Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of …
MK-1064
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
Matched Description: … MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics …
LB-100
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
Investigational
Matched Description: … LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or …
CXD101
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
Matched Description: … CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab …
mRNA-3351
mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome
Experimental
Matched Description: … mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. …
Displaying drugs 11376 - 11400 of 11784 in total